pharmaceutical research

The International Federation of Pharmaceutical Manufacturers and Associations argues that ethics should be re-centered as a core business strategy for the pharmaceutical industry, positioning ethical conduct not just as compliance but as a source of competitive advantage. The piece frames integrity in research, pricing and access as key to rebuilding public trust in drugmakers.

A study published in Nature reports that large language models tend to recommend the same branded drug names when answering medical queries, showing notable convergence across different systems. The finding raises questions about whether AI tools could skew pharmaceutical market exposure or reflect biases in their training data, and what that means for clinicians and patients relying on AI-generated medication advice.

CAR T-cell therapy, already approved for blood cancers, faces major hurdles in solid tumors, where hostile microenvironments suppress engineered immune cells. A new approach reported in pharmaceutical manufacturing coverage aims to build or arm CAR T cells directly inside tumor tissue, potentially improving persistence and reducing off-target effects. Researchers see in-situ engineering as a promising route to finally extend cell therapy beyond blood cancers, though clinical proof remains limited.

The Aging Research and Drug Discovery meeting (ARDD) 2026 is set to take place at Harvard, bringing together longevity scientists, pharmaceutical companies and regulators. The event is expected to focus on translating aging biology research into therapies and navigating regulatory pathways for longevity treatments, reinforcing the field's growing push toward mainstream drug development.

OpenAI has acquired a tool designed to accelerate drug development workflows, a field where research and testing are notoriously slow. The move signals OpenAI's push to apply its artificial intelligence beyond chatbots and into pharmaceutical research, where AI could shorten discovery timelines and reduce costs. Industry watchers see it as part of a broader race among AI companies to expand into science and healthcare applications.

OpenAI is reportedly entering drug development through a biotech startup, according to an exclusive report by Axios. The move would place the company directly in pharmaceutical research, using its artificial intelligence to help discover and design new drugs. Commenters see it as a sign AI is moving beyond chatbots into serious, real-world applications in medicine and science.

Varda Space Industries has launched its W-7 capsule mission to study the crystallization of cancer drug compounds in microgravity. The company says manufacturing pharmaceuticals in orbit can produce purer crystal structures than is possible on Earth, potentially improving drug formulations. It is the latest in Varda's series of orbital research missions, drawing attention to the growing commercial space manufacturing sector.

Drug discovery traditionally starts by selecting a molecular target and screening compounds against it. A counter-approach, sometimes called phenotypic screening, instead begins with observed results in cells or organisms, then works backwards to identify the mechanism. Discussion is circulating in the biotech and pharmaceutical community about whether results-first methods could uncover effective medicines that target-first research misses.

Drug discovery is increasingly relying on models designed to reflect human biology rather than animal data, but researchers are still debating what evidence is needed before such models can be trusted. The discussion centres on validation standards, data quality and how far computational or human-based systems can be relied upon when predicting how drugs will behave in patients.

A debate is under way in the pharmaceutical industry over whether clinical trials could gather less data while still protecting patient safety. Trials currently collect vast amounts of information, much of it rarely used, adding cost and slowing research. The question is whether streamlined data collection could make trials faster and cheaper without losing evidence needed to judge safety and efficacy.

Psychedelic science is being framed as an emerging frontier in medical research, with attention on whether substances like psilocybin and MDMA could yield new treatments for depression, PTSD and other hard-to-treat conditions. Discussion centres on clinical trial progress, regulatory hurdles and growing pharmaceutical interest in mind-altering compounds as potential medicines.

AstraZeneca has announced a partnership with Oracle to use artificial intelligence in running clinical trials. Under the collaboration, AI tools are expected to help speed up trial design, patient matching and data analysis in drug development. The move reflects a broader push by pharmaceutical companies to work with technology firms to make trials faster and more efficient, and news of the deal is being reported by major outlets including Reuters.

OpenAI has acquired an artificial intelligence biotech startup in a move aimed at helping scientists develop new drugs faster. The purchase signals OpenAI's push beyond chatbots and general AI into applied science, where machine learning is increasingly used to speed up drug discovery and research. The startup's name and deal value were not immediately disclosed.

Kevin Weil has left OpenAI and raised $215 million for a new drug discovery startup, according to Fortune. The move marks a shift from artificial intelligence to applying advanced computing to pharmaceutical research. The size of the funding round so early in the company's life is drawing attention across the tech and biotech communities.

The Medicine Maker reports on how genomic data is being used to tailor drug discovery to individual patients and genetic profiles. The piece examines how sequencing advances are helping researchers identify drug targets and develop personalized therapies rather than one-size-fits-all treatments. It reflects ongoing interest in precision medicine across the pharmaceutical industry.

Clinical Leader examines a growing worry in pharmaceutical research: what happens to a sponsor's clinical trial data and workflows when a software vendor goes out of business or is acquired. The piece raises questions of data ownership, vendor lock-in and continuity planning, a concern for trial sponsors relying on third-party platforms.

Pfizer has introduced an AI fluency program aimed at building artificial intelligence skills across its workforce. The initiative, described as teaching the company to 'speak AI,' signals the drugmaker's push to embed AI capabilities into its operations, from research to business processes. Details on scale, cost, and partners have not been made public, but the move fits a broader trend of pharmaceutical companies investing in AI training and tools.

French biotech Okomera has announced a commercial agreement with pharmaceutical company Servier to apply its tumor miniaturization technology to cancer research. The deal will let Servier use Okomera's platform, which miniaturizes tumor samples, in its oncology research work. Financial terms were not disclosed in the announcement.